Science For A Better Life
|
|
- Harvey Eaton
- 5 years ago
- Views:
Transcription
1 Science For A Better Life Bayer Cheuvreux German Corporate Conference Frankfurt, January 18, 2011 Werner Baumann, CFO
2 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Disclaimer
3 Who are we? Bayer Investor Presentation Cheuvreux German Corporate Conference Page 5 Bayer A Science Based Business Model Science For A Better Life Culture & Capabilities 12,400 people in R&D 3.1bn R&D budget in 2010 Global footprint Network with leading institutions Innovation Transformational latestage pharma pipeline Agchem pipeline with combined peak sales potential of 1.25bn New applications at MaterialScience Value Performance Customers Shareholders Employees Bayer Investor Presentation Cheuvreux German Corporate Conference Page 6 3
4 Bayer A Leader in Its Markets 16.0bn HealthCare Pharmaceuticals 10.5bn, leading positions in key categories 25% Consumer Health 5.5bn, OTC pharmaceuticals, blood glucose meters and veterinary medicines, global #2-4 53% 22% 6.5bn CropScience Agrochemicals and seeds & traits, global #2 in agrochemicals 7.5bn MaterialScience Polyurethanes and polycarbonates, global #1 Sales 2009: 31.2bn Break-down excluding reconciliation Bayer Investor Presentation Cheuvreux German Corporate Conference Page 7 Bayer Truly Global Footprint Jan-Sep 2010 sales by market 13% 3.4bn domestic sales 87% 26.1bn foreign sales Bayer Investor Presentation Cheuvreux German Corporate Conference Page 8 4
5 Bayer Our Most Important Markets bn % yoy Fx adjusted Sales by country Jan-Sep % +7% % % % +4% -6% 0% % +3% +7% +26% +10% +1% * Bayer Investor Presentation Cheuvreux German Corporate Conference Page 9 *Greater China includes PR China, Hongkong, Macau and Taiwan Bayer Track Record of Performance Underlying EBIT in million Underlying EBITDA-margin in % 1, , , , ,287 4, Bayer Investor Presentation Cheuvreux German Corporate Conference Page , Highlights Group sales of 31.2bn (-5.3%) EBITDA before special items of 6.5bn (-6.6%); 3rd highest ever Net income of 1.4bn (-20.9%) Net cash flow significantly improved to 5.4bn (+49.0%) Net financial debt reduced by 4.5bn to 9.7bn Unchanged DPS of 1.40 Group targets largely achieved * % vs As reported in respective year 2002 as reported in as reported in excluding H.C. Starck and Wolff Walsrode margin in 2002 as reported 5
6 9M 2010 Bayer Lifts Sales And Earnings Sales in million % portfolio & currency adj. EBITDA pre-special items in million Core EPS in 23,296 26,076 4,959 5, M 09 9M 10 +8% 9M 09 9M % 9M 09 9M % HealthCare Small sales growth and flat earnings CropScience Improvement in Q3 after tough 1H 10 MaterialScience Impressive recovery, sales and earnings significantly up Bayer Investor Presentation Cheuvreux German Corporate Conference Page 11 Bayer Significant Investment Opportunities 1 HealthCare Product launches including Xarelto, VEGF-Trap Eye, Beyaz Pipeline development Emerging markets 2 CropScience BioScience (seeds & traits) Emerging markets 3 MaterialScience Capacity increase, in particular China Restructuring program launched to free-up resources and address performance issues at HealthCare and CropScience Bayer Investor Presentation Cheuvreux German Corporate Conference Page 12 6
7 Redirection of Resources to Improve Efficiencies And Cut Costs Contribution by Subgroup Savings Initiative Holding & Admin. ~12% ~34% CropScience HealthCare ~54% Savings and efficiency initiative at HealthCare, CropScience and corporate level Annual cost savings of 800m starting 2013, reinvestment of ~50% One-time-charges of around 1bn by end of 2012, Plans include layoff of 4,500 people Bayer Investor Presentation Cheuvreux German Corporate Conference Page 13 We innovate Bayer Investor Presentation Cheuvreux German Corporate Conference Page 14 7
8 Pharma Pipeline Maturing What it does Status Cardiology Xarelto Riociguat inhibits blood clot formation lowers blood pressure in the lung 1st indication launched/ filed; phase III phase III Oncology Nexavar Regorafenib Alpharadin inhibits enzymes important for tumor growth inhibits enzymes important for tumor growth targeted treatment of bone metastases in prostate cancer launched, additional indications in phase II/III phase III phase III Eye Diseases VEGF Trap-Eye inhibits formation of new blood vessels phase III Imaging Florbetaben detects amyloid-betaplaques (Alzheimer s disease) phase III Bayer Investor Presentation Cheuvreux German Corporate Conference Page 15 Make Xarelto a success Bayer Investor Presentation Cheuvreux German Corporate Conference Page 16 8
9 Xarelto Blockbuster Opportunity in Anticoagulation Therapy 2009 estimated treatment days (market for anticoagulants) ~0.1bn ~0.35bn Primary VTE prevention excl. orthopedic surgery VTE prevention in adult patients after hip or knee replacement Acute indications Prevention of VTE in medically ill patients Secondary prevention of ACS Chronic indications Stroke prevention in atrial fibrillation Treatment and secondary prevention of VTE ~0.2bn ~0.4bn Bayer Investor Presentation Cheuvreux German Corporate Conference Page 17 ~1.6bn VTE: Venous thrombo-embolism ACS: Acute coronary syndrome In All 7 Phase III Studies Reported Xarelto Demonstrated an Excellent Clinical Profile Indication Study Clinical Trial Results # VTE prevention after orthopedic surgery Extended sec. prevention of VTE DVT treatment ,729 patients, Xarelto vs enoxaparin 1,197 patients, Xarelto vs placebo 3,449 patients, Xarelto vs enoxaprin followed by VKA Superior efficacy: 52% relative risk reduction* Rates of major bleeding low. No statistically significant difference Superior efficacy: 82% reduction of recurrent VTE Low incidence of major bleeding. No stat. significant difference Non-inferior efficacy - significantly improved net clinical benefit ** Composite of major and clinically relevant non major bleeding similar with numerically lower major bleedings Stroke prevention in atrial fibrillation 14,269 patients, Xarelto vs VKA Non-inferiority vs. warfarin in ITT and per-protocol population. Active treatment superior to warfarin in reducing the risk of stroke and non- CNS embolism in the safety population. Composite of major and clinically relevant non major bleeding similar #) Selection, for full data see publications: RECORD data published in NEJM and Lancet, EINSTEIN-Ext. presented at ASH 2009, EINSTEIN-DVT presented at ESC 2010; ROCKET-AF presented at AHA 2010 *) Symptomatic VTE + all-cause mortality in pooled analysis of RECORD 1-4 **) Secondary outcome defined as composite of primary efficacy endpoint plus major bleeding VTE: Venous thrombo-embolism; DVT: Deep vein thrombosis; VKA: Vitamin K antagonist; AF: Atrial fibrillation; ITT: Intention to treat Bayer Investor Presentation Cheuvreux German Corporate Conference Page 18 9
10 Xarelto Expected Upcoming Newsflow Data of MAGELLAN phase III trial in VTE prevention in medically ill patients Early 2011e Completion of phase III EINSTEIN-PE in VTE treatment and sec. prevention Summer 2011e Completion of phase III ATLAS TIMI 51 in secondary prevention of ACS Summer 2011e Filing for VTE prevention in medically ill patients / for secondary prevention of ACS Target: 2011 Bayer Investor Presentation Cheuvreux German Corporate Conference Page 19 ACS: Acute coronary syndrome PE: Pulmonary embolism VTE: Venous thromboembolism Strong data VEGF-Trap Eye Bayer Investor Presentation Cheuvreux German Corporate Conference Page 20 10
11 VEGF-Trap Eye Indication Study Clinical Trial Results # Wet AMD vs. Lucentis Primary efficacy endpoint met, non-inferiority demonstrated One year data demonstrated potential for less frequent dosing with comparable vision maintenance CRVO vs. sham control injection Primary efficacy endpoint met, demonstrating significant improvement in vision 56% of patients on VEGF-Trap Eye showed an improvement of vision of at least 15 letters after 6 months (vs. 12% in control) DME vs. laser treatment Encouraging Phase II data: primary endpoint met Visual acuity gains over 24 weeks were maintained or numerically improved up to completion of the study at week 52 #) Selection, for published details see BAYER press releases from November 22 and December 20, Further data planned to be presented at Angiogenesis Conference, Miami, Florida, February AMD: Age-related Macular Degeneration CRVO: Central Retinal Vein Occlusion DME: Diabetic Macular Edema Bayer Investor Presentation Cheuvreux German Corporate Conference Page 21 VEGF-Trap Eye Expected Upcoming News Flow Data from the CRVO phase III program 1H 2011e Filing for wet AMD 1H 2011e Full data from wet AMD phase III VIEW program 2011e AMD: Age-related Macular Degeneration CRVO: Central Retinal Vein Occlusion Bayer Investor Presentation Cheuvreux German Corporate Conference Page 22 11
12 Innovation Bioscience Bayer Investor Presentation Cheuvreux German Corporate Conference Page 23 Innovation Leadership in Agrochemicals, Promising BioScience Pipeline 23 new agrochemical active ingredients launched, generated sales of 2bn in Six new agrochemical substances with sales potential of more than 1bn to be launched E Expect 18 new BioScience products to be launched E Numerous early-stage research and early development projects in Crop Protection and BioScience Bayer Investor Presentation Cheuvreux German Corporate Conference Page 24 12
13 Grow BioScience Sales to 1.4bn by 2018 Planned sales development in million CAGR 12% >1,000 CAGR 11% > ~1,400 Key growth drivers Fast growing established business in cotton, canola, rice and vegetables Regional expansion and introduction of new varieties Exploit traits potential through licensing agreements Extension of our crop-portfolio Significant R&D investment (~ 130m in 2009; 200+m in 2012E) R&D capacities strengthened through acquisition of Athenix (2009) 2002* E 2015 E 2018 E *2002 sales pro-forma Bayer + Aventis CropScience First nine months adj. sales up 26% Bayer Investor Presentation Cheuvreux German Corporate Conference Page 25 New capacities in China Bayer Investor Presentation Cheuvreux German Corporate Conference Page 26 13
14 Pronounced Volume Recovery Drove Q3 MaterialScience Sales Above Pre-Crisis Level pre-crisis During 2009 lower selling prices reduced sales by 1.2bn Sales in billion % yoy, Fx adj. Volumes % yoy Prices % yoy uebitda* margin Q3 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Bayer Investor Presentation Cheuvreux German Corporate Conference Page 27 * = EBITDA pre-special items Economic Recovery Accelerated Business Shift to Asia MaterialScience Sales in Asia/Pacific in % 21% bn sales (1-9) 28% 2.1bn sales Bayer Investor Presentation Cheuvreux German Corporate Conference Page 28 14
15 1bn New Investments to Support Future Growth Asia/Pacific is leading the recovery China already is the world s largest PCS market China is set to become the world s largest PUR market by 2015 Commitment to growth in China 2.1bn investment program in integrated polymer site in Shanghai, China until 2012 New investment of approx. 1bn in Shanghai by 2016 to Increase MDI capacity to 1,000kt/year More than double PCS capacity to 500kt/year Increase HDI capacity, new 50kt/year line planned Transfer of PCS Headquarters from Leverkusen to Shanghai Increasing downstream presence (investment of 110m by 2012) Bayer Investor Presentation Cheuvreux German Corporate Conference Page 29 PCS = Polycarbonates PUR = Polyurethanes Focus Emerging markets Bayer Investor Presentation Cheuvreux German Corporate Conference Page 30 15
16 Performance of Top 15 Large Pharma Companies in The Pharmerging Markets Bayer shows: Best ability to adapt to local markets 35% 30% Superior local execution capabilities A stable senior leadership team Continuous investments in mature products (Glucobay or Adalat) % CAGR % 20% 15% 10% 5% AZ J&J LILLY MERCK WYETH ABBOTT ROCHE BMS PFIZER GSK B-I NOVARTIS S-P S-A BAYER 0% 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% 22% % 2009 Revenue (Bubble size shows Pharmerging market sales)* Source : IMS Health Incorporates Pharmerging shake-up 2010 Bayer Investor Presentation Cheuvreux German Corporate Conference Page 31 Bayer is One of The Leading International HealthCare Companies in China HealthCare m +26% y-o-y (Fx-adj.) Impressive growth Driven by both Pharma (+23%) and Consumer Health (+35%) Pharma portfolio includes innovative products like Nexavar, Scilin Insulin and Xarelto Significant investment commitment Top products Glucobay Adalat Approx. 4,500 employees 100m over 5 years to set-up a global R&D center in China Avelox Aspirin Cardio Ultravist Nexavar 5% 10% 15% 20% 25% 30% 35% 70% Beijing manufacturing site expansion (~ 45m through 2015) Partnership with Tsinghua University (joint drug discovery, student support) Bayer Investor Presentation Cheuvreux German Corporate Conference Page 32 All growth rates are Fx-adj. Greater China includes PR China, Hongkong, Macau and Taiwan 16
17 CropScience in Brazil Strong Growth in One of the World s Largest Agchem Markets In million Brazil is the 2nd largest market for CropScience Bayer is one of the leading suppliers and growing strongly (20% CAGR between 2006 and 2009) Risk management systems in place to limit the potential impact of reduced credit availability CropScience sales CAGR +20% (+20%) Barter business expanded Bayer Investor Presentation Cheuvreux German Corporate Conference Page 33 Emerging Markets Drive Growth And Contribute Significantly to Group Sales In million, % yoy Fx adjusted 9M 10 Group sales by region Emerging Economies +29% USA +2% 21% 35% Emerging Economies¹ +17% ~3, % ~2, % +11% 34% 10% ~1,500 ~1,200 Western Europe +4% Others² +5% Group 26,076m; +8% Emerging Asia³ Latin America Eastern Europe Africa & Middle East Bayer Investor Presentation Cheuvreux German Corporate Conference Page 34 ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia minus Japan, Australia, New Zealand 17
18 Progress Outlook Bayer Investor Presentation Cheuvreux German Corporate Conference Page 35 Full Year 2010 Group Outlook Projects Strong Growth Over 2009 Sales Fx and portfolio adjusted E Q3 Update Sales 31.2bn -6% >5% confirmed uebitda 6.5bn -7% > 7bn confirmed Core EPS % >15% confirmed Bayer Investor Presentation Cheuvreux German Corporate Conference Page 36 Outlook depends on planning assumptions as detailed in the 2009 annual report 18
19 2010 A Year of Significant Progress New management Performance challenges in HealthCare and CropScience addressed Pharma pipeline maturing Xarelto demonstrated excellent clinical profile in important chronic indications Strong emerging markets growth - new investment program for MaterialScience in China First 9 month group performance solid, 2010 outlook projects strong growth over 2009 Optimistic for future developments Bayer Investor Presentation Cheuvreux German Corporate Conference Page 37 More Information? Join Our Meet Management Conference Bayer Analyst and Investor Day in Leverkusen Start: Tuesday, March 22, 2011 at 6:30 p.m. CET End: Wednesday, March 23, 2011 at approx. 3:30 p.m. CET. Program: Tuesday evening: Dinner hosted by Marijn Dekkers, CEO of Bayer AG Wednesday: Meet representatives of the Bayer AG and subgroup management boards. The focus will be on dialogue and open discussions in small groups without formal presentations. Meet Management 2011 Bayer Investor Presentation Cheuvreux German Corporate Conference Page 38 19
20 Reporting Events and AGM Date Monday, February 28, 2011 Thursday, April 28, 2011 Friday, April 29, 2011 Monday, May 02, 2011 Thursday, July 28, 2011 Thursday, October 27, 2011 Event Investor Conference Call Investor Conference Call Annual General Meeting Payment of Dividend Investor Conference Call Investor Conference Call Publication Full Year 2010 Results Annual Report First Quarter Results Stockholders Newsletter Second Quarter Results Stockholders Newsletter Third Quarter Results Stockholders Newsletter Bayer Investor Presentation Cheuvreux German Corporate Conference Page 39 Investor Relations Contacts Dr. Alexander Rosar Head of Investor Relations Phone: Dr. Jürgen Beunink Phone: Judith Nestmann Phone: Peter Dahlhoff Phone: Dr. Olaf Weber Phone: Fabian Klingen Phone: Bayer Investor Presentation Cheuvreux German Corporate Conference Page 40 20
Dr. Marijn Dekkers June Roadshow New York & Boston
Dr. Marijn Dekkers June 2010 Roadshow New York & Boston 100616 Bayer Key Characteristics A leader in its markets Business portfolio aligned to growth markets Well-proven and clear strategy Track-record
More informationBayer aligns organization with Life Science businesses
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer aligns organization with Life Science businesses Operational management in three divisions: Pharmaceuticals,
More informationSandra E. Peterson appointed new Chairman of the Board of Management of Bayer CropScience
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sandra E. Peterson appointed new Chairman of the Board of Management of Bayer CropScience Current Chairman Prof.
More informationConference Call Q2 2013
Conference Call Düsseldorf, July 30, GEA Group Aktiengesellschaft Disclaimer Forward-looking statements are based on our current assumptions and forecasts. These statements naturally entail risks and uncertainties,
More informationLUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017
LUPIN LIMITED Investor Presentation February 09, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based
More informationQ Presentation Preliminary Results FY 2011
Presentation Preliminary Results FY Düsseldorf, February 6, 2012 GEA Group Disclaimer All figures for are preliminary and have therefore not yet been audited. The yearend financial statements for the GEA
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationBayer Supervisory Board decides company s future management line-up:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Supervisory Board decides company s future management line-up: Dr. Marijn E. Dekkers to be new CEO of Bayer
More informationLupin Limited Annual Results FY12. Investor Presentation May being
Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR
More informationDriving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China
Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant
More informationAnnual Press Conference Financial year 2017
Annual Press Conference 2018 Financial year 2017 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017 Highly successful financial year 2017 Major success with human pharmaceuticals
More informationConfirms 2013 Financial Guidance
Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared
More informationTextron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported
More informationDealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.
Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:
More informationKKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn
More informationTextron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook
Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS
More informationInnovation and the Changing Practice of Medicine
Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis
More informationTextron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%
Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third
More informationSafe Harbor Disclosure
Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts are forward-looking statements. The company generally
More information2Q 2016 Results. Mermaid Maritime Plc. August 2016
Mermaid Maritime Plc 2Q 2016 Results August 2016 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to
More informationPROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS
PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA
More informationLUPIN LIMITED. Q2 FY18 Investor Presentation. October 30, 2017
LUPIN LIMITED Q2 FY18 Investor Presentation October 30, 2017 Lupin is a Dominant Force in Global Generics Globally 8 th 6 th 2 nd #1 largest generic globally (by market cap 1 ) largest generic company
More information1Q 2016 Results. Mermaid Maritime Plc. May 23, 2016
Mermaid Maritime Plc 1Q 2016 Results May 23, 2016 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated or distributed to
More informationAstraZeneca 2013 AGM
AstraZeneca 2013 AGM Chief Executive s Remarks 25 April 2013 Introduction Thank you, Leif. Ladies and gentlemen, good afternoon. I would like to add my own welcome to you this afternoon and thank you for
More informationVisionWorks. Roadmap to Profitable Growth. Gottfried Plumpe. Member of the Board, Bayer MaterialScience
VisionWorks Roadmap to Profitable Growth Gottfried Plumpe Member of the Board, Bayer MaterialScience CSFB Field Trip September 22, 2004 Safe Harbor This presentation contains forward-looking statements
More information2Q 2017 Results. 11 Aug 2017 MERMAID MARITIME PUBLIC COMPANY LIMITED
MERMAID MARITIME PUBLIC COMPANY LIMITED 2Q 2017 Results 11 Aug 2017 1 Disclaimer: The information contained in this document is intended only for use during the presentation and should not be disseminated
More information4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. Inc. Investor Update February 1, 2019 Key Metrics Assets Under Management Management Fees ($ in billions) ($ in millions) $195 $1,069 $168 $905 $100 $107
More informationInterim Report Q3 2007
Interim Report Q3 2007 - Orders received and margins - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström President and CEO Alfa Laval Group Key figures
More informationThird Quarter 2014 Results
Third Quarter 204 Results November 4, 204 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationAlfa Laval Slide 1
Alfa Laval Slide 1 www.alfalaval.com Interim Report Q2 2008 - Orders received and margins - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström President
More informationFirst Quarter 2014 Results
First Quarter 04 Results May 6, 04 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationMessage from the CEO. 4 OMRON Corporation
Message from the CEO 4 OMRON Corporation Achieving growth through a stronger earnings structure. Solving social issues through new technologies and innovative concepts. Yoshihito Yamada President and CEO
More informationCONTACTS: Michaela Hessling Executive Director Corporate Communications Tel
Aurubis continues developing its strategy Group working on a more effective organization, an increase in productivity and a sustainable improvement in earnings Resolution for dividend payment of 1.10 per
More informationCapcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2018
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) 3rd Quarter Report Fiscal year ending March 31, 2018 0 Forward-looking Statements Strategies, plans, outlooks and other statements that are
More informationFY2016 Full-Year Earnings & New Medium-term Management Plan VG2.0 VG2.0. April 27, 2017 OMRON Corporation
FY2016 Full-Year Earnings & New Medium-term Management Plan VG2.0 VG2.0 April 27, 2017 OMRON Corporation Contents 1. FY2016 Results & EARTH-1 STAGE Review (FY2014 FY2016) 2. New Medium-term Management
More information4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)
More informationInvestor Presentation. November 2018
Investor Presentation November 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn of Assets $81bn Private Equity, Growth Equity
More informationImplantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,
Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User
More informationAlf a Lav al Slide 1
Alf a Lav al Slide 1 www.alfalaval.com Interim Report Q2 2007 - Orders received and margins - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström President
More informationLONG TERM VALUE CREATION BLAKE JORGENSEN, CFO
LONG TERM VALUE CREATION BLAKE JORGENSEN, CFO SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are subject to change. Statements including words such as anticipate, "believe,
More informationSecond Quarter CY 2012 Results. August 2, 2012
Second Quarter CY 2012 Results August 2, 2012 1 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts
More informationTHE STARS GROUP 2017 ANNUAL AND SPECIAL MEETING MANAGEMENT PRESENTATION MAY 10, 2018, TORONTO, 11:30 (ET)
Please Note: THE STARS GROUP 2017 ANNUAL AND SPECIAL MEETING MANAGEMENT PRESENTATION MAY 10, 2018, TORONTO, 11:30 (ET) Some of our comments today will contain forward-looking information and statements
More informationAlfa Laval Slide 1
Alfa Laval Slide 1 www.alfalaval.com Interim Report Q1 2008 - Orders received and margins - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström President
More informationBioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market
More informationM. Kevin McEvoy. Oceaneering International, Inc. Chief Executive Officer 2015 GLOBAL ENERGY AND POWER EXECUTIVE CONFERENCE JUNE 2, 2015 NEW YORK, NY
2015 GLOBAL ENERGY AND POWER EXECUTIVE CONFERENCE JUNE 2, 2015 NEW YORK, NY M. Kevin McEvoy Chief Executive Officer Oceaneering International, Inc. Safe Harbor Statement Statements we make in this presentation
More informationHBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company
More informationFourth Quarter 2013 Results. February 6, 2014
Fourth Quarter 2013 Results February 6, 2014 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts
More informationAqua Pharmaceuticals, LLC
Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing
More informationAbbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO
Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking
More informationSecond Quarter 2013 Results August 1, 2013
Second Quarter 203 Results August, 203 2 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationJ.P. Morgan Healthcare Conference Summary Transcript
J.P. Morgan Healthcare Conference Summary Transcript Good afternoon, everyone. I'm Shigeo Taniuchi. I'm President and COO of Santen Pharmaceutical. I joined Santen in 1996, and I became the President and
More information2 nd Quarter Earnings Conference Call
2 nd Quarter Earnings Conference Call KKR & Co. Inc. Investor Update July 26, 2018 Recent Milestones K-1 $ Converted to a Corporation on July 1, 2018 Investor Day held on July 9, 2018 2 Key Metrics Assets
More informationState of Licensing 2011 Update
State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-
More informationRoche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd.
Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo 2011 Dr. Axel Braun F. Hoffmann La Roche Ltd. Content Roche Company Profile The IP Department Patent Filings Global Strategy Sales Overview IP
More informationCapcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements
More informationBayer R&D Investor Day 2005
Science For A Better Life MaterialScience Bayer R&D Investor Day 2005 December 8, 2005 London Bayer R&D Investor Day 2005 Successful Process Innovation Across the Portfolio Ian Paterson Board Member Innovation
More informationFor personal use only
2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor
More informationDaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector
More informationCapital One Securities, Inc.
Capital One Securities, Inc. 10 th Annual Energy Conference December 9, 2015 New Orleans, LA Alan R. Curtis SVP and Chief Financial Officer Oceaneering International, Inc. Safe Harbor Statement Statements
More informationAlfa Laval Slide 1
Alfa Laval Slide 1 www.alfalaval.com Interim Report Q1 2006 - Orders received and margins - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström President
More information21 st Annual Needham Growth Conference
21 st Annual Needham Growth Conference Investor Presentation January 15, 2019 Safe Harbor Statement The information contained in and discussed during this presentation may include forward-looking statements
More informationROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.
ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU. Can you guess? How does one protect their brand? Most brands are distinct and being distinctive is the way potential users
More informationKKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018
KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)
More informationFourth Quarter and Year End 2001 Conference Call, February 20, 2002 Dr. Metin Colpan, Managing Director and CEO Peer M. Schatz, Managing Director and
Fourth Quarter and Year End 2001 Conference Call, February 20, 2002 Dr. Metin Colpan, Managing Director and CEO Peer M. Schatz, Managing Director and CFO Forward Looking Statements Certain of the statements
More informationSecond Quarter 2015 Results
Second Quarter 205 Results August 4, 205 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained in this presentation that are not historical facts are forward-looking
More informationQuarterly presentation Q DOF Subsea Group
Quarterly presentation Q1 2016 DOF Subsea Group DOF Subsea Group DOF Subsea Group in brief Fleet One of the largest subsea vessel owners in the world Owns and operates a fleet of 21 vessels, plus 4 newbuilds
More informationSecond Quarter 2014 Results
Second Quarter 2014 Results August 5, 2014 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are not historical facts are
More informationFirst Quarter CY 2012 Results. May 9, 2012
First Quarter CY 2012 Results May 9, 2012 2012 Activision Blizzard 1 Safe Harbor Disclosure Please review our SEC filings on Form 10-K and Form 10-Q The statements contained in this presentation that are
More informationAlfa Laval Slide 1
Alfa Laval Slide 1 www.alfalaval.com Interim Report Q4 2005 - Orders received, margins and dividend - Highlights - Development per segment - Geographical development - Financials - Outlook Mr. Lars Renström
More informationQ Presentation for Roadshows and Conferences GEA continuing operations
2014 Presentation for Roadshows and Conferences GEA continuing operations Düsseldorf, May 06, 2014 GEA Group Disclaimer Forward-looking statements are based on our current assumptions and forecasts. These
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2019
More informationTextron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance
Corporate Communications Department NEWS Release Textron Reports Third Quarter 2018 Results; Narrows Full-Year EPS and Cash Guidance $468 million returned to shareholders through share repurchases Completed
More informationKaro Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
More informationExecutive Summary World Robotics 2018 Industrial Robots
Executive Summary World Robotics 2018 Industrial Robots 13 Executive Summary World Robotics 2018 Industrial Robots Robot Sales 2017: Impressive growth In 2017, robot sales increased by 30% to 381,335 units,
More informationAnnual Shareholders' Meeting. Stuttgart May 14th 2009
Annual Shareholders' Meeting Stuttgart May 14th 2009 HUGO BOSS in 2008 in EUR mill. Net Sales 1.686 + 6% (fx-adj.) + 3% Gross Profit 1.011 + 7% EBIT before extraordinary items 226 + 9% Cash Flow from operating
More informationGSK PLC. GSK PLC presentation delivered at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2018 at 10:30 AM
GSK PLC GSK PLC presentation delivered at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2018 at 10:30 AM James Gordon: Good morning. I'm James Gordon, JPMorgan European Pharmaceutical
More informationSurgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing
Surgical Sutures Market By Product Type [Automated Suturing Devices (Disposable Automated Suturing Devices, And Re-Usable Automated Suturing Devices), and Sutures (Sutures by Type (Absorbable & Non-Absorbable),
More informationThomson Reuters Legal
Reuters/Suhaib Salim Peter Warwick President & CEO Deutsche Bank European TMT Conference September 9, 2010 Thomson Reuters Special Note Safe Harbor / Forward-Looking Statements The following discussion
More informationOphthotech, Novartis in ex-u.s. pact worth up to $1B, with $200M up front May 20, 2014 By Randy Osborne Audience Reach: 3,110
Ophthotech, Novartis in ex-u.s. pact worth up to $1B, with $200M up front May 20, 2014 By Randy Osborne Audience Reach: 3,110 Still signing up patients for its phase III trial with Fovista, the antiplatelet-derived
More informationHY2015. Disciplined performance management. Redefining the future for people and places 1. Attractive growth fundamentals & opportunities
HY2015 Attractive growth fundamentals & opportunities Disciplined performance management Redefining the future for people and places 1 Overview Resilient underlying performance HY2015 Headline EPS 31.3p
More information3 rd Annual Global Automotive Conference Goldman Sachs. London, December 8, 2011
3 rd Annual Global Automotive Conference Goldman Sachs London, December 8, 2011 1 3rd Annual Global Automotive Conference Goldman Sachs London, December 8, 2011 Outline Net sales: Sustained firm growth
More informationInvestor Presentation
Connecting What s Needed with What s Next Investor Presentation September 2017 Forward-Looking Statements Statements we make in this presentation that express a belief, expectation, or intention are forward
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationPierre Brondeau Vice President, Business Group Executive Electronic Materials Regional Director - Europe Lehman Brothers Conference Call November
Pierre Brondeau Vice President, Business Group Executive Electronic Materials Regional Director - Europe Lehman Brothers Conference Call November 2006 Forward Looking Statement The presentation today may
More informationFOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationErratum to the Press Release 2017 annual results - NRJ Group. dated March 15, 2018
Paris, March 20, 2018 5:45 pm Erratum to the Press Release 2017 annual results - NRJ Group dated March 15, 2018 An editorial error was made in the press release dated March 15, 2018 (English version only)
More informationEmcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationInvestor Presentation & Financial Highlights. November 2018
Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.
More informationFirst Quarter 2017 Results. May 4, 2017
First Quarter 207 Results May 4, 207 Safe Harbor Disclosure Please review our SEC filings on Form 0-K and Form 0-Q The statements contained herein that are not historical facts are forward-looking statements,
More information4Q February 2011
4Q 2010 28 February 2011 2 Disclaimer forward looking statements This presentation contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
More informationHalliburton and Baker Hughes Creating the leading oilfield services company
Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com
More informationPareto Securities 20 th Annual Oil & Offshore Conference. Dan Rabun, Chairman & CEO. 4 September 2013
Pareto Securities 20 th Annual Oil & Offshore Conference Dan Rabun, Chairman & CEO 4 September 2013 1 Forward-Looking Statements Statements made today that are not historical facts are forward-looking
More informationMid-Atlantic Investor Meetings. February 2013
Mid-Atlantic Investor Meetings February 2013 1 Forward-Looking Statements Statements made today that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities
More informationRod Larson President & CEO
Connecting What s Needed with What s Next Rod Larson President & CEO J.P. Morgan Energy Equity Conference June 27, 2017 New York, NY Forward-Looking Statements Statements we make in this presentation that
More informationACTIVISION BLIZZARD ANNOUNCES BETTER-THAN-EXPECTED SECOND QUARTER 2011 FINANCIAL RESULTS
Contacts: Kristin Southey SVP, Investor Relations (310) 255-2635 ksouthey@activision.com Maryanne Lataif SVP, Corporate Communications (310) 255-2704 mlataif@activision.com FOR IMMEDIATE RELEASE ACTIVISION
More informationHasbro First Quarter 2016 Financial Results Conference Call Management Remarks April 18, 2016
Hasbro First Quarter 2016 Financial Results Conference Call Management Remarks April 18, 2016 Debbie Hancock, Hasbro, Vice President, Investor Relations: Thank you and good morning everyone. Joining me
More informationIn the quarter, Textron returned $344 million to shareholders through share repurchases, compared to $186 million in the first quarter of 2017.
Corporate Communications Department NEWS Release Textron Reports First Quarter 2018 Income from Continuing Operations of $0.72 per Share; Signs Agreement to Sell Tools & Test Business for $810 Million
More informationThe partner of choice for self-care products
The partner of choice for self-care products Venture Life Group plc Full Year Results Presentation 2017 22 March 2018 2017 highlights Revenues up 12% to 16.1m (2016: 14.3m) Gross profit increased 18% to
More informationApril, 2014 GameAccount Network
April, 2014 Disclaimer Certain statements included in this Presentation contain forward-looking information concerning GameAccount Network's strategy, operations, financial performance or condition, outlook,
More informationPreferred partner. Aker Solutions. Nordic Energy Summit 2013, 21 March Leif Borge CFO
Aker Solutions Nordic Energy Summit 213, 21 March Leif Borge CFO 212 Aker Solutions Slide 1 This is Aker Solutions Employees: 19 5 Contract staff: 5 5 Revenues: 45 bn EBITDA: 4.7 bn Market Cap: 32. bn
More information